New York, December 17, 2015 -- Albany Molecular Research, Inc. (AMRI) announced today the acquisition of pharmaceutical testing and consulting services provider Whitehouse Labs for $54 million in cash. The acquisition is credit positive because it expands AMRI's service offerings and improves growth without materially increasing leverage. There is no change to ratings, including the B3 Corporate Family Rating or the stable outlook.
Vollständigen Artikel bei Moodys lesen